|
|
OSUCCC
 |
Michael A. Caligiuri, M.D.
Director, Comprehensive Cancer Center
Professor
College of Medicine
Internal Medicine/ OSUCCC - Hematology/Oncology
521B James Cancer Hospital
300 W. 10th Avenue Columbus,OH. 43210
o |
(614) 293-7521 |
f |
(614) 293-3122 |
|
Programs
|
 |
In July 2003, Dr. Caligiuri, a medical scientist who has conducted extensive research in leukemia, lymphoma and immunology, was named director of the OSU Comprehensive Cancer Center (OSUCCC) and deputy director of The James Cancer Hospital and Solove Research Institute.
Dr. Caligiuri is a professor of medicine and a Distinguished University Scholar who holds the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research.
Caligiuri's laboratory, which has nearly 40 members, focuses on research in leukemia, lymphoma and the human immune system.
His current projects include developing a vaccine to prevent lymphoma in organ transplant patients and working to target genetic defects in leukemia and lymphoma for curative therapies. Research efforts led by Caligiuri at OSU have received more than $20 million from the National Cancer Institute, including a $9.5 million program project grant to study immunity in cancer.
Caligiuri earned his graduate and medical degrees at Stanford University School of Medicine, then trained in internal medicine, oncology, bone marrow transplantation and immunology at Harvard before joining the Harvard Medical School faculty in 1989. He later went to Roswell Park Medical Center in Buffalo, NY, and was recruited to the OSUCCC in 1997 as associate director for clinical research. He has more than 130 publications in scientific journals.
For more information on Dr. Caligiuri's research, click here > Caligiuri Lab
To download a copy of Dr. Caligiuri's CV, click here > Dr. Caligiuri's CV
|
|
Current Publications
|
|
Leuk Res in press: , 2009
|
|
A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.
|
|
Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA
|
|
|
Leukemia 23(5): 912-8, 2009
|
|
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
|
|
Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC
|
|
|
J Immunol 183(8): 4968-74, 2009
|
|
CD94 defines phenotypically and functionally distinct mouse NK cell subsets.
|
|
Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM Jr, Caligiuri MA
|
|
|
Blood 114(13): 2667-77, 2009
|
|
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
|
|
Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N
|
|
|
J Clin Oncol 27(19): 3198-204, 2009
|
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrozek, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
|
|
|
Blood 113(17): 4008-10, 2009
|
|
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.
|
|
Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo GJ, Yu J, Caligiuri MA
|
|
|
Blood 113(12): 2706-14, 2009
|
|
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.
|
|
Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA
|
|
|
Blood 113(11): 2470-7, 2009
|
|
The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.
|
|
Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA
|
|
|
Br J Haematol 144(6): 848-55, 2009
|
|
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
|
|
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
Blood 113(22): 5558-67, 2009
|
|
TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.
|
|
Yu J, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, Visser J, Marcucci G, Plass C, Belyavsky AV, Caligiuri MA
|
|
|
Clin Cancer Res 14(2): 569-78, 2008
|
|
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
|
|
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC
|
|
|
Breast Cancer Res Treat 117(1): 83-9, 2008
|
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
|
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL
|
|
|
Blood 111(4): 2364-73, 2008
|
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
|
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G
|
|
|
J Allergy Clin Immunol 120(4): 924-31, 2008
|
|
Chronic lymphocytosis of functionally immature natural killer cells.
|
|
French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
|
|
|
Blood 111(8): 4173-83, 2008
|
|
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
|
|
Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, Caligiuri MA, Tridandapani S, Burry RW, Carson WE, Carson WE 3rd
|
|
|
Blood 110(5): 1648-55, 2008
|
|
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
|
|
Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ
|
|
|
Blood 112(5): 2013-6, 2008
|
|
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
|
|
Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA
|
|
|
Blood 111(3): 1552-9, 2008
|
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
|
Whitman SP, Ruppert AS, Radmacher MD, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K
|
|
|
J Clin Invest 117(9): 2408-21, 2008
|
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
|
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D
|
|
|
Blood 112(3): 461-9, 2008
|
|
Human natural killer cells.
|
|
Caligiuri MA
|
|
|
Blood 111(2): 816-28, 2008
|
|
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
|
|
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D
|
|
|
Blood 111(9): 4723-30, 2008
|
|
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
|
|
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
J Clin Oncol 26(30): 4934-9, 2008
|
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA
|
|
|
N Engl J Med 358(18): 1919-28, 2008
|
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
|
Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
|
|
|
J Immunother 31(8): 685-92, 2008
|
|
Natural killer cells in innate immunity and cancer.
|
|
Becknell B, Caligiuri MA
|
|
|
Blood 110(6): 2075-83, 2008
|
|
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
|
|
Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R
|
|
|
J Clin Oncol 26(31): 5078-87, 2008
|
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
|
Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD
|
|
|
Genes Chromosomes Cancer 47(3): 253-9, 2008
|
|
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
|
|
Swanson KD, Winter JM, Reis M, tires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, Look AT, Kucherlapati R, Kern SE, Meyerson M, Neel BG, Bentires-Alj M
|
|
|
Proc Natl Acad Sci U S A 104(39): 15400-5, 2008
|
|
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.
|
|
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G
|
|
|
Blood 110(7): 2569-77, 2008
|
|
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
|
|
Zhao XB, Lapalombella R, Joshi T, Cheny C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kusewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC, Zhao X, Cheney C
|
|
|
J Immunol 181(6): 3784-92, 2008
|
|
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
|
|
Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA
|
|
|
Blood 112(6): 2508-11, 2008
|
|
The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.
|
|
Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, Caligiuri MA
|
|
|
J Exp Med 204(10): 2397-405, 2008
|
|
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.
|
|
Trotta R, Ciarlariello D, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA, Dal Col J, Allard J 2nd
|
|
|
Eur J Immunol 37(9): 2549-61, 2008
|
|
Transcriptional control of human T-BET expression: the role of Sp1.
|
|
Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, Marcucci G, Wu LC, Caligiuri MA
|
|
|
PLoS One 3(9): e3180, 2008
|
|
Tumor growth decreases NK and B cells as well as common lymphoid progenitor.
|
|
Richards J, McNally B, Fang X, Caligiuri MA, Zheng P, Liu Y
|
|
|
J Clin Oncol 26(28): 4595-602, 2008
|
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD
|
|
|
